Stoneprime US has the mission to accelerate breakthroughs in biotechnology and healthcare by leveraging the power of artificial intelligence (AI) to identify, invest in, and support innovative biotech companies. We aim to foster cutting-edge research and create values for our stakeholders through our strategic investments and AI-driven decision-making.
Antonio is an entrepreneur with 10+ years of experience in the Fintech & AI world, principally in the fields of Biotech, Finance and Energy.
He is Founder of Euklid, an alternative investment fund with strategies totally driven by Artificial Intelligence, CIO & Co-Founder of Quaternion Technology, an IT advisory company that develops algorithms for electric trading strategies and financial asset managers.
Antonio is CEO of Stoneprime, an Italian company that assesses the development potential of over 500 companies in the Biotech sector with Artificial Intelligence.
Antonio has also been a speaker since 2018 and a member of the Future Investment Initiative Institute in Riyadh, sponsored by the Public Investment Fund on Fintech and AI, Professor of ‘Data – driven models for investment’, a course on Artificial Intelligence at LUISS Guido Carli in Rome and friend of Aspen Institute.
Antonio is responsible for overseeing the day-to-day operations of the company and ensuring that the company is running efficiently and effectively, making strategic decisions for Stoneprime US.
Giorgio has a vast experience in Bioinformatics & Data Analytics sector, combining experiences from the laboratory to the supercomputer with +10 years of experience in data analysis for life sciences, having published +40 papers in peer-reviewed international journals and 1 academic book and presenting data, analysis and business plans to executives, investors, and VC during fundraising.
Giorgio holds a PhD in Computational Biology, a Postdoctoral Fellow at University of Florida in host-microbe interactions and is currently earning an MBA.
Giorgio is a visionary leader and a distinguished scientist in the realm of bioinformatics, a discipline that seamlessly bridges the gap between advanced computational biology and transformative biotech innovations. Giorgio is responsible for providing strategic leadership and overall direction, driving innovation, setting a technology roadmap, and ensuring that the company remain at the forefront of advances in the Biotech & AI industry.
Giorgio brings 15+ years of experience in life sciences data analysis coupled with a proven track record of business leadership within the corporate environment. His work – documented by over 50 peer-reviewed papers, academic books and multiple patents – reflects a commitment to biotech innovation. His background includes pivotal roles at Exagen, Metabiomics, Evolve BioSystems and research at NASA, University of Florida and Northern Arizona University.
Giorgio holds an MSc in Medical Biotechnologies and a PhD in Computational Biology. He has completed a postdoctoral fellowship at the University of Florida, and is currently enriching his scientific expertise with strategic business leadership skills through an Executive MBA program.
Emanuele is Co-Founder and LLM Data Scientist at StonePrime US.
He holds a Master’s degree in Physics of Complex Systems from Politecnico di Torino and is currently pursuing a PhD in Computer Science at KAUST (King Abdullah University of Science and Technology), Saudi Arabia, where his research focuses on Trustworthy AI and Small Language Models.
At StonePrime US, Emanuele leads the research function and oversees collaboration with KAUST, while working closely with the technical team to manage the full AI pipeline from foundational research and model development to signal generation.
Portfolio Manager with more than ten years’ experience in the wealth management market; after the graduation in finance at Bocconi University, he began working in one of the most prominent family offices in Italy, being also Co-Founder & Strategist at StonePrime.
Claudio has been CFA since 2018, and his work focuses on developing tools, models, strategies and reports for portfolio construction and rebalancing.
He also provides guidelines for the financial products, manages positions and risk and evaluates developments and improvements in the underlying product.
Managing Partner and Portfolio Manager at Quintessential Capital Management, a long/short global equity fund based in NYC aiming to provide investors with exceptional returns leveraging on the principles of value and activist investing.
The Fund invests through a concentrated portfolio of high-quality businesses acquired at a discount to intrinsic value and shorts based on insights from in-depth, investigative due diligence.
He specializes in value investing and deep, investigative-style due diligence. His specialty lies in detecting, investigating, shorting and exposing public fraudulent or criminal corporations.
Gabriele holds a BA from Tufts University and an MBA at SDA Bocconi. He has recently started a another degree in physics and mathematics.
James Hodson is the CEO and Board Member of the AI for Good Foundation, a non-profit organization that uses artificial intelligence to solve global problems.
Hodson used to be a manager of AI research at Bloomberg LP, where they oversaw a team of 20+ researchers and software engineers focused on building sophisticated platforms for knowledge representation, reasoning, inference, structured prediction and cross-lingual understanding. Hodson has also worked as a research assistant at Princeton University. James holds a degree in Computer Science from Princeton University.
James Hodson has a degree in machine translation and a field in machine translation, philosophy of science, and computer science from Princeton University.
He is a researcher, leader and entrepreneur in the fields of Artificial Intelligence and Economics, with particular focus on Sustainable Development, Global Information Flows, Natural Language Processing and modelling interactions in highly complex dynamic systems.
Simona Tiribelli is Director for AI Ethics of the Institute for Technology & Global Health at the MIT-funded spinoff PathCheck Foundation (Boston, US), assistant professor at the University of Macerata (Italy), where she teaches Ethics of Artificial Intelligence and Global Justice and Technology, 2023 visiting scholar in AI ethics at the New York University (NYU), and 2020 Fulbright awarded and fellow at the MIT Media Lab, Massachusetts Institute of Technology, US.
She is a founder of the Spinoff GAIA (AI Ethics and Governance) and AI Ethics advisor for companies in Europe and US.
She authored two books and a number of articles in leading scientific international journals on ethics of artificial intelligence and digital technology, and delivered on invite more than 50 talks in prestigious academic institutions such as Harvard University, Tufts University, Toronto University, and many more, in Europe, Canada, and USA.
Roberto Maiolino is Professor of Experimental Astrophysics at the Department of Physics (Cavendish Laboratory) and at the Kavli Institute for Cosmology, University of Cambridge, Honorary Professor at University College London and Royal Society Research Professor.
He received his MS in Physics at the University of Florence in 1992 and the PhD in Astronomy at the University of Florence in 1996, with a secondment at the Steward Observatory at the University of Arizona as a visiting scholar.
In 2018 he was knighted by the Italian President in the Order of the Star of Italy. In 2019 he was appointed Honorary Professor at University College London.
His main area of research is the investigation of the formation and evolution of galaxies and supermassive black holes by using various observing facilities.
Prof. Italiano is Professor of Computer Science at LUISS Guido Carli University.
He received a Ph.D. in Computer Science from Columbia University in 1991. He worked at IBM’s T. J. Watson Research Laboratories, Yorktown Heights, NY, USA from 1991 to 1996. In 1994, at the age of 33, he won the national competition for full professor, and returned to Italy as a full professor first at the University of Salerno and then at “Ca’ Foscari” University of Venice.
He is a member of the Editorial Board of several international scientific journals. He has been invited to give papers for many international conferences and he has been invited to the scientific program committees (Program Committee) of numerous international conferences and symposia.
He is the author or co-author of more than 250 scientific publications in prestigious international computer science journals and conferences. He has served as a computer science consultant for large international companies in Italy and the United States (AT&T, IBM, Lucent Bell Labs, and Microsoft).
Adriana Chiarelli, a biotechnologist with a Ph.D. in Microbiology, brings over 5 years of expertise in managing wet-lab operations, conducting genome sequence analysis, and leading applied research projects in antimicrobial resistance and microbial preservation.
In her role as Scientific Project Manager at the Biological Resources Centre of the Pasteur Institute (CRBIP) from 2021 to 2023, Adriana orchestrated transversal activities, focusing on maximizing the value of microbial resources preserved at CRBIP and exploring the potential biotechnological applications of microbes. Her active engagement in EU collaborative initiatives and consortia.
Maddalena Pacelli, holds a bachelor’s degree in biotechnology and a master’s degree in genetics and molecular biology.
Currently pursuing a Ph.D. in life sciences and a Master’s in entrepreneurship and innovation, she has gained international research experiences in top-level centres in Italy (Sapienza University of Rome, Italian Institute of Technology), Germany (Berlin Institute for Medical Systems Biology – Max Delbruck Centre) and Israel (Weizmann Institute of Science), reflecting her commitment to global scientific endeavours.
Passionate about personalized medicine, Maddalena oversees the creation and management of the biotech branch of Eupaxx S.p.A. Her expertise encompasses genomics, immunotherapy, drug design and delivery, showcasing a holistic approach to integrating technology, such as AI, for impactful advancements in the pursuit of innovative and cutting-edge solutions.
Geoffrey Stephens is an experienced Ph.D. scientific executive with 20+ years working in all aspects of large and small biotechnology companies. Skilled in large and small molecules, drug development, molecular biology, biotechnology, cell culture, and bioinformatics. Demonstrated record in driving complicated projects to IND in autoimmune and oncology spaces. Strong scientific background with early training at the NIH/NIAID.
Extensive experience supervising groups of laboratory professionals in immunology-based experimentation, process development, and sophisticated data-mining for uncovering unique patterns in data. Previous experience includes regulatory T cells, CAR-T, TCR-T, large and small molecule therapeutics for cancer, autoimmunity, and inflammatory diseases.
Dr. Stephens led teams discovering biologics across all stages of development while he was at AstraZeneca (AZ)/MedImmune.
During his tenure there, he identified several targets that were ultimately developed to various stages in the AZ pipeline for the treatment of autoimmune/inflammatory diseases. Dr. Stephens also played an integral role in the development and eventual FDA approval of Benralizamab (Fasenra), an anti-IL-5Ra specific antibody for the treatment of asthma. More recently, he was the Head of Process Development at Tessa Therapeutics developing CD30-CAR-T cell therapies for the treatment of Hodgkin and non-Hodgkin lymphoma, which received RMAT and PRIME designations from the FDA and EMA, respectively.
Prior to that, Dr. Stephens was the Director of Product Science at Immatics, LLC, where he led the development of TCR-T cell-based therapies for the treatment of a variety of cancers. Geoffrey also co-founded and was the Chief Scientific Officer of Cellcion, LLC, a company devoted to the development of software platforms for the analysis of complex immunological systems.
